AXSM analyst estimates

Axsome Therapeutics (AXSM) analyst ratings, the average price target and its range, and every firm's latest call.

AXSM analyst ratings and price targets

DateFirmCallTarget
Oct 26, 2026Piper SandlerAxsome Therapeutics price target lowered to $238 from $258 at Piper Sandler$238.00
Oct 8, 2026RBC CapitalAxsome Therapeutics price target lowered to $295 from $297 at RBC Capital$295.00
Sep 29, 2026Deutsche BankAxsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank$267.00
Sep 25, 2026Morgan StanleyAxsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley$247.00
Sep 23, 2026Truist FinancialTruist Securities Starts Axsome Therapeutics (AXSM) at Buy$285.00
Aug 12, 2026Mizuho SecuritiesAxsome Therapeutics (AXSM) PT Raised to $316 at Mizuho$316.00
Aug 11, 2026Wells FargoAxsome Therapeutics price target raised to $256 from $255 at Wells Fargo$256.00
Aug 11, 2026GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim$275.00
Aug 11, 2026NeedhamAxsome Therapeutics (AXSM) PT Raised to $268 at Needham$268.00
Aug 11, 2026Morgan StanleyAxsome Therapeutics price target raised to $251 from $242 at Morgan Stanley$251.00
Aug 11, 2026RBC CapitalAxsome Therapeutics price target lowered to $297 from $304 at RBC Capital$297.00
Jul 20, 2026BMO CapitalAxsome Therapeutics initiated with an Outperform at BMO Capital$310.00
Jul 7, 2026RBC CapitalAxsome Therapeutics price target raised to $304 from $302 at RBC Capital$304.00
Jun 11, 2026JefferiesAxsome Therapeutics (AXSM) PT Raised to $380 at Jefferies$380.00
May 5, 2026Deutsche BankAxsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank$280.00

Updated 2026-11-02 17:50 UTC